Patricia Anne Maryland
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Privia Health to Report Q3 2026 Results on Nov 5. Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.
Transaction History
| SGRY | ▼ Sell | Open Market | 20,018 | $455K | 8/11/2025 | View on chart |
| EHC | ▲ Buy | Grant | 24 | $0 | 7/15/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 6,861 | $160K | 6/10/2025 | View on chart |
| PRVA | ▲ Buy | Grant | 8,396 | $0 | 5/21/2025 | View on chart |
| EHC | ▲ Buy | Grant | 1,424 | $0 | 5/1/2025 | View on chart |
| EHC | ▲ Buy | Grant | 23 | $0 | 4/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 25 | $0 | 1/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 24 | $0 | 10/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 24 | $0 | 7/15/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 6,170 | $160K | 6/6/2024 | View on chart |
| PRVA | ▲ Buy | Grant | 11,124 | $0 | 5/22/2024 | View on chart |
| EHC | ▲ Buy | Grant | 1,978 | $0 | 5/2/2024 | View on chart |
| EHC | ▲ Buy | Grant | 21 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 24 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 27 | $0 | 10/16/2023 | View on chart |
| EHC | ▲ Buy | Grant | 25 | $0 | 7/17/2023 | View on chart |
| PRVA | ▲ Buy | Grant | 7,758 | $0 | 7/1/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 4,192 | $160K | 6/1/2023 | View on chart |
| EHC | ▲ Buy | Grant | 2,385 | $0 | 5/4/2023 | View on chart |
| EHC | ▲ Buy | Grant | 22 | $0 | 4/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 22 | $0 | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 27 | $0 | 10/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 50 | $0 | 7/20/2022 | View on chart |
| PRVA | ▲ Buy | Grant | 7,425 | $0 | 5/27/2022 | View on chart |
| SGRY | ▲ Buy | Grant | 4,030 | $160K | 5/20/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,226 | $0 | 5/5/2022 | View on chart |
| EHC | ▲ Buy | Grant | 20 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 23 | $0 | 1/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 21 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.